Register Login

Immunocore Holdings plc (IMCR)

(10% Negative) Immunocore Holdings plc (IMCR) Announces Delay in outcomes Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 12:14 p.m.

    📋 Immunocore Holdings plc (IMCR) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 07:11:43

    Event Type: Clinical Trial Update

    Event Details:

    Immunocore Holdings plc (IMCR) Announces Clinical Trial Update Immunocore Holdings plc (IMCR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: outcomes
    • Clinical Stage: Phase 1, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: J.P. Morgan Healthcare Conference

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Immunocore Holdings plc
    • CIK: 0001671927
    • Ticker Symbol: IMCR
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories